Experimental Drug Trial for Bundibugyo Ebola Virusa

EXPERIMENTAL DRUG TRIAL FOR BUNDIBUGYO EBOLA VIRUS

Why in the News?

  • Clinical Trial: The Democratic Republic of Congo (DRC) has launched a clinical trial to evaluate Gilead Sciences’ experimental antiviral drug Obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola virus outbreak in Congo and Uganda.
  • Research Initiative: The study seeks to determine whether early antiviral treatment after exposure can prevent Ebola Virus Disease (EVD) and strengthen global outbreak preparedness.

experimental drug trial, Bundibugyo Ebola virus, Ebola virus treatment, Ebola research, viral outbreak, clinical trial, experimental medicine, infectious disease, hemorrhagic fever, public health, virology, medical research, virus treatment, Ebola update, disease control

OBELDESIVIR CLINICAL TRIAL

  • Trial Objective: The study will assess whether Obeldesivir can prevent the development of Ebola infection when administered within five days of high-risk exposure.
  • Target Population: Around 1,000 participants aged 12 years and above, exposed to confirmed Ebola cases but not yet symptomatic, will be enrolled.
  • Collaborative Effort: The trial is led by DRC’s National Institute for Biomedical Research (INRB) and France’s ANRS Emerging Infectious Diseases, with support from ALIMA, Médecins Sans Frontières (MSF), and Gilead Sciences.
  • Monitoring Process: Participants will be monitored daily for 21 days, followed by a final assessment on Day 42 to evaluate safety and effectiveness.
  • Expected Impact: Successful results could establish the first post-exposure antiviral therapy against the Bundibugyo Ebola strain, improving future epidemic response.

BUNDIBUGYO EBOLA VIRUS

  • About the Virus: Bundibugyo ebolavirus is one of the six recognised species of the Ebolavirus genus and causes Ebola Virus Disease (EVD), a severe viral haemorrhagic fever.
  • Transmission: The virus spreads through direct contact with infected blood, body fluids, contaminated materials, or infected animals, especially fruit bats and non-human primates.
  • Clinical Features: Symptoms include fever, weakness, headache, vomiting, diarrhoea, and bleeding, with severe cases progressing to multi-organ failure.
  • Current Treatment: Management primarily relies on supportive care, while vaccines are currently available mainly for the Zaire Ebola virus; no approved vaccine exists specifically for the Bundibugyo strain.
  • Global Concern: Periodic outbreaks in Central and East Africa highlight the need for rapid surveillance, diagnostics, therapeutics, and international public health cooperation.

EBOLA VIRUS DISEASE (EVD)

●  About Ebola: Ebola Virus Disease (EVD) is a zoonotic viral haemorrhagic fever caused by viruses of the Filoviridae family, first identified in 1976 in present-day Democratic Republic of Congo and Sudan.

●  Reservoir Host: Fruit bats (Pteropodidae family) are considered the natural reservoir, with spillover occurring to humans through infected wildlife.

●  WHO Response: The World Health Organization (WHO) coordinates surveillance, laboratory support, vaccination strategies, case management, and emergency response during Ebola outbreaks.

●  Prevention Measures: Key measures include contact tracing, isolation of cases, infection prevention and control (IPC), safe burials, vaccination where applicable, and community awareness.

●  UPSC Relevance: Important for GS Paper III (Science & Technology and Health) and Prelims under emerging infectious diseases, zoonotic diseases, epidemic preparedness, WHO, and global health governance.